Skip to content

Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection

RecruitingPhase 4NCT07018375
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The primary objective is to evaluate the impact of oliceridine versus sufentanil for perioperative analgesia on the incidence of chronic postsurgical pain (CPSP) with functional impact in patients undergoing video-assisted thoracoscopic surgery.

Study details

Official title
Effect of Oliceridine-based Intravenous Patient-Controlled Analgesia on Chronic Postsurgical Pain After Video-Assisted Thoracoscopic Lung Resection: A Multicenter Randomized Double-Blind Controlled Trial Protocol
Interventions
Sponsor
Tianjin Medical University General Hospital
Collaborators
The No. 2 Hospital of Baoding; Tianjin Cancer Hospital Airport Hospital; Tianjin Medical University Second Hospital; North China University of Science and Technology; Haibin People's Hospital of Tianjin Binhai New Area; The People's Hospital of Jizhou District, Tianjin
Start date
2026-01-06
Primary completion
2027-03-31
Sex
All
Age range
from 18 Years to 75 Years
Results posted
No results posted in this snapshot
Countries
China
Total sites listed
7

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18-75 years * ASA physical status I-III * BMI 18-35 kg/m² * Scheduled for unilateral video-assisted thoracoscopic surgery (VATS) lung resection, including wedge resection, segmentectomy, lobectomy, or radical resection for lung cancerresection for lung cancer * Preoperative Numeric Rating Scale (NRS) pain score of 0 * Ability to understand the study objectives and procedures, with voluntary informed consent obtained * Expected postoperative recovery in the general ward setting Exclusion Criteria: * History of chronic pain or long-term analgesic use prior to surgery * Previous ipsilateral thoracic surgery * Prior neoadjuvant radiotherapy or chemotherapy * Severe cardiovascular or cerebrovascular disease, or hepatic/renal dysfunction (ALT/AST \> 3 × upper limit of normal; eGFR \< 60 mL/min/1.73 m²) * Severe or unstable psychiatric disorders requiring psychoactive medication (e.g., schizophrenia, bipolar disorder), or cognitive impairment precluding reliable self-report * Other concurrent active malignancy or active infection * Known hypersensitivity to study medications (opioids, adjuvant analgesics, anesthetics, or antiemetics) * Pregnancy, lactation, or planned pregnancy during the study period * Participation in another interventional clinical trial within 3 months before enrolment * Any condition deemed unsuitable for study participation by the investigator

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07018375